Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia

Posted by rob on April 14, 2009 under Uncategorized | Comments are off for this article

Chronic myelogenous leukemia (CML) is one of the myeloproliferative disorders. It accounts for 15[ndash]20% of all leukemias in adults. The mainstay of diagnosis is the detection of Philadelphia chromosome or one of its products. Tyrosine kinase inhibitors changed the paradigm of treating such disease with the good responses. However, they do have side effects. In our case we will report tumor lysis syndrome happening after starting Imatinib myselate. We did a literature review and looked all the cases that documented this complication. (Source: Journal of Clinical Pharmacy and Therapeutics)